Phase II study of 4'-epi-doxorubicin in metastatic renal cancer.
In 20 patients with measurable metastatic renal cancer 4'-epi-doxorubicin (Adriamycin) administration (75 mg/m2, every 3 weeks) did not result in any tumor remission. Hematologic and gastrointestinal toxicity was generally mild to moderate. Anthracycline-induced cardiac side effects were not observed in any of the patients.
D000328:Adult; D000368:Aged; D004317:Doxorubicin / Q000627:therapeutic use* / Q000633:toxicity; D004341:Drug Evaluation; D015251:Epirubicin; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis
D015251:Epirubicin; D004317:Doxorubicin